The dynamic lives of macrophage and dendritic cell subsets in atherosclerosis

Annals of the New York Academy of Sciences

Volumn 1319, Issue 1, 2014, Pages 19-37

  Taghavie Moghadam, Parésa L ^a   Butcher, Matthew J ^a   Galkina, Elena V ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Atherosclerosis; Dendritic cell; Immune response; Inflammation; Macrophage

Indexed keywords

ARTERY WALL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BONE MARROW CELL; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; NONHUMAN; PLASMACYTOID DENDRITIC CELL;

ATHEROSCLEROSIS; DENDRITIC CELL; IMMUNE RESPONSE; INFLAMMATION; MACROPHAGE;

ADAPTIVE IMMUNITY; ANIMALS; ATHEROSCLEROSIS; DENDRITIC CELLS; HUMANS; MACROPHAGES;

EID: 84902959992     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12392     Document Type: Article

References (155)

1. Murray, C.J., T. Vos, R. Lozano, et al. 2012. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2197-2223.
2. Thompson, R.C., A.H. Allam, G.P. Lombardi, et al. 2013. Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations. Lancet 381: 1211-1222.
3. Konstantinov, I.E., N. Mejevoi & N.M. Anichkov. 2006. Nikolai N. Anichkov and his theory of atherosclerosis. Tex. Heart Inst. J. 33: 417-423.
4. Mayerl, C., M. Lukasser, R. Sedivy, et al. 2006. Atherosclerosis research from past to present-on the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf Virchow. Virchows Arch. 449: 96-103.
5. Ross, R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340: 115-126.
6. Hopkins, P.N. 2013. Molecular biology of atherosclerosis. Physiol. Rev. 93: 1317-1542.
7. Libby, P., A.H. Lichtman & G.K. Hansson. 2013. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 38: 1092-1104.
8. Lichtman, A.H., C.J. Binder, S. Tsimikas & J.L. Witztum. 2013. Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J. Clin. Invest. 123: 27-36.
9. Moore, K.J., F.J. Sheedy & E.A. Fisher. 2013. Macrophages in atherosclerosis: a dynamic balance. Nat. Rev. Immunol. 13: 709-721.
10. Galkina, E. & K. Ley. 2009. Immune and inflammatory mechanisms of atherosclerosis Annu. Rev. Immunol. 27: 165-197.
11. Tabas, I. 2010. Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10: 36-46.
12. Gautier, E.L., C. Jakubzick & G.J. Randolph. 2009. Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29: 1412-1418.
13. Fogg, D.K., C. Sibon, C. Miled, et al. 2006. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science 311: 83-87.
14. Serbina, N.V. & E.G. Pamer. 2006. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat. Immunol. 7: 311-317.
15. Hilgendorf, I. & F.K. Swirski. 2012. Making a difference: monocyte heterogeneity in cardiovascular disease. Curr. Atheroscler. Rep. 14: 450-459.
16. Geissmann, F., M.G. Manz, S. Jung, et al. 2010. Development of monocytes, macrophages, and dendritic cells. Science 327: 656-661.
17. Tacke, F., D. Alvarez, T.J. Kaplan, et al. 2007. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Invest. 117: 185-194.
18. Swirski, F.K., P. Libby, E. Aikawa, et al. 2007. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J. Clin. Invest. 117: 195-205.
19. Koltsova, E.K., Z. Garcia, G. Chodaczek, et al. 2012. Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. J. Clin. Invest. 122: 3114-3126.
20. Auffray, C., D. Fogg, M. Garfa, et al. 2007. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 317: 666-670.
21. Carlin, L.M., E.G. Stamatiades, C. Auffray, et al. 2013. Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. Cell 153: 362-375.
22. Hanna, R.N., I. Shaked, H.G. Hubbeling, et al. 2012. NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis. Circ. Res. 110: 416-427.
23. Chao, L.C., E. Soto, C. Hong, et al. 2013. Bone marrow NR4A expression is not a dominant factor in the development of atherosclerosis or macrophage polarization in mice. J. Lipid Res. 54: 806-815.
24. Zhao, Y., D.A. Howatt, F. Gizard, et al. 2010. Deficiency of the NR4A orphan nuclear receptor NOR1 decreases monocyte adhesion and atherosclerosis. Circ. Res. 107: 501-511.
25. Combadiere, C., S. Potteaux, M. Rodero, et al. 2008. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 117: 1649-1657.
26. Saederup, N., L. Chan, S.A. Lira & I.F. Charo. 2008. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis. Circulation 117: 1642-1648.
27. Landsman, L., L. Bar-On, A. Zernecke, et al. 2009. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 113: 963-972.
28. White, G.E. & D.R. Greaves. 2012. Fractalkine: a survivor's guide: chemokines as antiapoptotic mediators. Arterioscler. Thromb. Vasc. Biol. 32: 589-594.
29. Swirski, F.K., M. Nahrendorf, M. Etzrodt, et al. 2009. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325: 612-616.
30. Robbins, C.S., A. Chudnovskiy, P.J. Rauch, et al. 2012. Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions. Circulation 125: 364-374.
31. Yvan-Charvet, L., T. Pagler, E.L. Gautier, et al. 2010. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 328: 1689-1693.
32. Murphy, A.J., M. Akhtari, S. Tolani, et al. 2011. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J. Clin. Invest. 121: 4138-4149.
33. Robbins, C.S., I. Hilgendorf, G.F. Weber, et al. 2013. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat. Med. 19: 1166-1172.
34. Jakubzick, C., E.L. Gautier, S.L. Gibbings, et al. 2013. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity 39: 599-610.
35. Desurmont, C., J.M. Caillaud, F. Emmanuel, et al. 2000. Complete atherosclerosis regression after human ApoE gene transfer in ApoE-deficient/nude mice. Arterioscler. Thromb. Vasc. Biol. 20: 435-442.
36. Llodra, J., V. Angeli, J. Liu, et al. 2004. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc. Natl. Acad. Sci. U. S. A. 101: 11779-11784.
37. Potteaux, S., E.L. Gautier, S.B. Hutchison, et al. 2011. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. J. Clin. Invest.121: 2025-2036.
38. Trogan, E., J.E. Feig, S. Dogan, et al. 2006. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 103: 3781-3786.
39. Feig, J.E., I.Pineda-Torra, M. Sanson, et al. 2010. LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J. Clin. Invest. 120: 4415-4424.
40. Feig, J.E., J.X. Rong, R. Shamir, et al. 2011. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc. Natl. Acad. Sci. U. S. A. 108: 7166-7171.
41. Feig, J.E., Y. Shang, N. Rotllan, et al. 2011. Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages. PLoS One 6: e28534.
42. Gautier, E.L., S. Ivanov, P. Lesnik & G.J. Randolph. 2013. Local apoptosis mediates clearance of macrophages from resolving inflammation in mice. Blood 122: 2714-2722.
43. van Gils, J.M., M.C. Derby, L.R. Fernandes, et al. 2012. The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques. Nat. Immunol. 13: 136-143.
44. van Gils, J.M., B. Ramkhelawon, L. Fernandes, et al. 2013. Endothelial expression of guidance cues in vessel wall homeostasis dysregulation under proatherosclerotic conditions. Arterioscler. Thromb. Vasc. Biol. 33: 911-919.
45. Wanschel, A., T. Seibert, B. Hewing, et al. 2013. Neuroimmune guidance cue Semaphorin 3E is expressed in atherosclerotic plaques and regulates macrophage retention. Arterioscler. Thromb. Vasc. Biol. 33: 886-893.
46. Ramkhelawon, B., Y. Yang, J.M. vanGils, et al. 2013. Hypoxia induces netrin-1 and Unc5b in atherosclerotic plaques: mechanism for macrophage retention and survival. Arterioscler. Thromb. Vasc. Biol. 33: 1180-1188.
47. Geissmann, F., S. Gordon, D.A. Hume, et al. 2010. Unravelling mononuclear phagocyte heterogeneity. Nat. Rev. Immunol. 10: 453-460.
48. Gordon, S. & P.R. Taylor. 2005. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5: 953-964.
49. Gordon, S. & F.O. Martinez. 2010. Alternative activation of macrophages: mechanism and functions. Immunity 32: 593-604.
50. Sica, A. & A. Mantovani. 2012. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122: 787-795.
51. Mosser, D.M. & J.P. Edwards. 2008. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8: 958-969.
52. Martinez, F.O., S. Gordon, M. Locati & A. Mantovani. 2006. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 177: 7303-7311.
53. Nathan, C.F., H.W. Murray, M.E. Wiebe & B.Y. Rubin. 1983. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med. 158: 670-689.
54. Verreck, F.A., B.T. de, D.M. Langenberg, et al. 2004. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc. Natl. Acad. Sci. U. S. A. 101: 4560-4565.
55. Ziegler, H.K., L.K. Staffileno & P. Wentworth. 1984. Modulation of macrophage Ia-expression by lipopolysaccharide. I. Induction of Ia expression in vivo. J. Immunol. 133: 1825-1835.
56. Stein, M., S. Keshav, N. Harris & S. Gordon. 1992. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J. Exp. Med. 176: 287-292.
57. Shnyra, A., R. Brewington, A. Alipio, et al. 1998. Reprogramming of lipopolysaccharide-primed macrophages is controlled by a counterbalanced production of IL-10 and IL-12. J. Immunol. 160: 3729-3736.
58. Moore, K.J. & I. Tabas. 2011. Macrophages in the pathogenesis of atherosclerosis. Cell 145: 341-355.
59. Clinton, S.K., R. Underwood, L. Hayes, et al. 1992. Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am. J. Pathol. 140: 301-316.
60. Khallou-Laschet, J., A. Varthaman, G. Fornasa, et al. 2010. Macrophage plasticity in experimental atherosclerosis. PLoS One 5: e8852.
61. Kadl, A., A.K. Meher, P.R. Sharma, et al. 2010. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ. Res. 107: 737-746.
62. Bouhlel, M.A., B. Derudas, E. Rigamonti, et al. 2007. PPAR[gamma] activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 6: 137-143.
63. Gleissner, C.A., I. Shaked, C. Erbel, et al. 2010. CXCL4 downregulates the atheroprotective hemoglobin receptor CD163 in human macrophages. Circ. Res. 106: 203-211.
64. Gleissner, C.A., I. Shaked, K.M. Little & K. Ley. 2010. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J. Immunol. 184: 4810-4818.
65. -/- mice. Thromb. Haemost. 98: 1108-1113.
66. Barajas, B., N. Che, F. Yin, et al. 2011. NF-E2-related factor 2 promotes atherosclerosis by effects on plasma lipoproteins and cholesterol transport that overshadow antioxidant protection. Arterioscler. Thromb. Vasc. Biol. 31: 58-66.
67. Freigang, S., F. Ampenberger, G. Spohn, et al. 2011. Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur. J. Immunol. 41: 2040-2051.
68. Sussan, T.E., J. Jun, R. Thimmulappa, et al. 2008. Disruption of Nrf2, a key inducer of antioxidant defenses, attenuates ApoE-mediated atherosclerosis in mice. PLoS One 3: e3791.
69. Ruotsalainen, A.K., M. Inkala, M.E. Partanen, et al. 2013. The absence of macrophage Nrf2 promotes early atherogenesis. Cardiovasc. Res. 98: 107-115.
70. Cole, J.E., E. Georgiou & C. Monaco. 2010. The expression and functions of Toll-like receptors in atherosclerosis. Mediators Inflamm. 2010: 393946.
71. Kzhyshkowska, J., C. Neyen & S. Gordon. 2012. Role of macrophage scavenger receptors in atherosclerosis. Immunobiology 217: 492-502.
72. Kunjathoor, V.V., M. Febbraio, E.A. Podrez, et al. 2002. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 277: 49982-49988.
73. Stewart, C.R., L.M. Stuart, K. Wilkinson, et al. 2010. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 11: 155-161.
74. Seimon, T.A., M.J. Nadolski, X. Liao, et al. 2010. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 12: 467-482.
75. Moore, K.J., V.V. Kunjathoor, S.L. Koehn, et al. 2005. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J. Clin. Invest. 115: 2192-2201.
76. Manning-Tobin, J.J., K.J. Moore, T.A. Seimon, et al. 2009. Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. Arterioscler. Thromb. Vasc. Biol. 29: 19-26.
77. Duewell, P., H. Kono, K.J. Rayner, et al. 2010. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464: 1357-1361.
78. Grebe, A. & E. Latz. 2013. Cholesterol crystals and inflammation. Curr. Rheumatol. Rep. 15: 313.
79. Spann, N.J., L.X. Garmire, J.G. McDonald, et al. 2012. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell 151: 138-152.
80. Boyle, J.J., P.L. Weissberg & M.R. Bennett. 2003. Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler. Thromb. Vasc. Biol. 23: 1553-1558.
81. Boyle, J.J., P.L. Weissberg & M.R. Bennett. 2002. Human macrophage-induced vascular smooth muscle cell apoptosis requires NO enhancement of Fas/Fas-L interactions. Arterioscler. Thromb. Vasc. Biol. 22: 1624-1630.
82. Butcher, M.J. & E.V. Galkina. 2012. Phenotypic and functional heterogeneity of macrophages and dendritic cell subsets in the healthy and atherosclerosis-prone aorta. Front Physiol. 3: 44.
83. Galis, Z.S., M. Muszynski, G.K. Sukhova, et al. 1994. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ. Res. 75: 181-189.
84. Krausgruber, T., K. Blazek, T. Smallie, et al. 2011. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 12: 231-238.
85. Liao, X., N. Sharma, F. Kapadia, et al. 2011. Kruppel-like factor 4 regulates macrophage polarization. J. Clin. Invest. 121: 2736-2749.
86. Hagemann, T., T. Lawrence, I. McNeish, et al. 2008. "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 205: 1261-1268.
87. Duluc, D., M. Corvaisier, S. Blanchard, et al. 2009. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int. J. Cancer 125: 367-373.
88. Robbins, C.S. & F.K. Swirski. 2010. The multiple roles of monocyte subsets in steady state and inflammation. Cell Mol. Life Sci. 67: 2685-2693.
89. Jenkins, S.J., D. Ruckerl, P.C. Cook, et al. 2011. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 332: 1284-1288.
90. Chorro, L., A. Sarde, M. Li, et al. 2009. Langerhans cell (LC) proliferation mediates neonatal development, homeostasis, and inflammation-associated expansion of the epidermal LC network. J. Exp. Med. 206: 3089-3100.
91. Davies, L.C., M. Rosas, P.J. Smith, et al. 2011. A quantifiable proliferative burst of tissue macrophages restores homeostatic macrophage populations after acute inflammation. Eur. J. Immunol. 41: 2155-2164.
92. Hashimoto, D., A. Chow, C. Noizat, et al. 2013. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 38: 792-804.
93. Ajami, B., J.L. Bennett, C. Krieger, et al. 2011. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat. Neurosci. 14: 1142-1149.
94. Gordon, D., M.A. Reidy, E.P. Benditt & S.M. Schwartz. 1990. Cell proliferation in human coronary arteries. Proc. Natl. Acad. Sci. U. S. A. 87: 4600-4604.
95. Lutgens, E., E.D. deMuinck, P.J. Kitslaar, et al. 1999. Biphasic pattern of cell turnover characterizes the progression from fatty streaks to ruptured human atherosclerotic plaques. Cardiovasc. Res. 41: 473-479.
96. Rosenfeld, M.E. & R. Ross. 1990. Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis 10: 680-687.
97. Bennett, M.R., G.I. Evan & S.M. Schwartz. 1995. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J. Clin. Invest. 95: 2266-2274.
98. Geng, Y.J. & P. Libby. 1995. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am. J. Pathol. 147: 251-266.
99. Van Vré, E.A., H. Ait-Oufella, A. Tedgui & Z. Mallat. 2012. Apoptotic cell death and efferocytosis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 32: 887-893.
100. Ravichandran, K.S. 2011. Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. Immunity 35: 445-455.
101. Elliott, M.R., F.B. Chekeni, P.C. Trampont, et al. 2009. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461: 282-286.
102. Gude, D.R., S.E. Alvarez, S.W. Paugh, et al. 2008. Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a "come-and-get-me" signal. FASEB J. 22: 2629-2638.
103. Lauber, K., E. Bohn, S.M. Krober, et al. 2003. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 113: 717-730.
104. Truman, L.A., C.A. Ford, M. Pasikowska, et al. 2008. CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood 112: 5026-5036.
105. Weigert, A., S. Cremer, M.V. Schmidt, et al. 2010. Cleavage of sphingosine kinase 2 by caspase-1 provokes its release from apoptotic cells. Blood 115: 3531-3540.
106. Green, D.R., T. Ferguson, L. Zitvogel & G. Kroemer. 2009. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 9: 353-363.
107. Schrijvers, D.M., G.R. DeMeyer, M.M. Kockx, et al. 2005. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25: 1256-1261.
108. Babaev, V.R., J.D. Chew, L. Ding, et al. 2008. Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis. Cell Metab. 8: 492-501.
109. Liu, J., D.P. Thewke, Y.R. Su, et al. 2005. Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low-density lipoprotein receptor-null mice. Arterioscler. Thromb. Vasc. Biol. 25: 174-179.
110. Boesten, L.S., A.S. Zadelaar, N.A. van, et al. 2009. Macrophage p53 controls macrophage death in atherosclerotic lesions of apolipoprotein E deficient mice. Atherosclerosis 207: 399-404.
111. Arai, S., J.M. Shelton, M. Chen, et al. 2005. A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development. Cell Metab. 1: 201-213.
112. Bhatia, V.K., S. Yun, V. Leung, et al. 2007. Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice. Am. J. Pathol. 170: 416-426.
113. Boisvert, W.A., D.M. Rose, A. Boullier, et al. 2006. Leukocyte transglutaminase 2 expression limits atherosclerotic lesion size. Arterioscler. Thromb. Vasc. Biol. 26: 563-569.
114. Bolick, D.T., M.D. Skaflen, L.E. Johnson, et al. 2009. G2A deficiency in mice promotes macrophage activation and atherosclerosis. Circ. Res. 104: 318-327.
115. Ait-Oufella, H., K. Kinugawa, J. Zoll, et al. 2007. Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation 115: 2168-2177.
116. Ait-Oufella, H., V. Pouresmail, T. Simon, et al. 2008. Defective mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28: 1429-1431.
117. -/- mice. Arterioscler. Thromb. Vasc. Biol. 28: 1421-1428.
118. Komura, H., M. Miksa, R. Wu, et al. 2009. Milk fat globule epidermal growth factor-factor VIII is down-regulated in sepsis via the lipopolysaccharide-CD14 pathway. J. Immunol. 182: 581-587.
119. Driscoll, W.S., T. Vaisar, J. Tang, et al. 2013. Macrophage ADAM17 deficiency augments CD36-dependent apoptotic cell uptake and the linked anti-inflammatory phenotype. Circ. Res. 113: 52-61.
120. Thorp, E., T. Vaisar, M. Subramanian, et al. 2011. Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase Cdelta, and p38 mitogen-activated protein kinase (MAPK). J. Biol. Chem. 286: 33335-33344.
121. Zhao, X.Q., M.W. Zhang, F. Wang, et al. 2011. CRP enhances soluble LOX-1 release from macrophages by activating TNF-alpha converting enzyme. J. Lipid Res. 52: 923-933.
122. Rafatian, N., D. Karunakaran, K.J. Rayner, et al. 2013. Cathepsin G deficiency decreases complexity of atherosclerotic lesions in apolipoprotein E-deficient mice. Am. J. Physiol. Heart Circ. Physiol. 305: H1141-H1148.
123. Hansson, G.K. & A. Hermansson. 2011. The immune system in atherosclerosis. Nat. Immunol. 12: 204-212.
124. Galkina, E. & K. Ley. 2007. Vascular adhesion molecules in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27: 2292-2301.
125. Paulson, K.E., S.N. Zhu, M. Chen, et al. 2010. Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. Circ. Res. 106: 383-390.
126. Niessner, A. & C.M. Weyand. 2010. Dendritic cells in atherosclerotic disease. Clin. Immunol. 134: 25-32.
127. Zhu, S.N., M. Chen, J.Jongstra-Bilen & M.I. Cybulsky. 2009. GM-CSF regulates intimal cell proliferation in nascent atherosclerotic lesions. J. Exp. Med. 206: 2141-2149.
128. Ganguly, D., S. Haak, V. Sisirak & B. Reizis. 2013. The role of dendritic cells in autoimmunity. Nat. Rev. Immunol. 13: 566-577.
129. Segura, E. & S. Amigorena. 2013. Inflammatory dendritic cells in mice and humans. Trends Immunol. 34: 440-445.
130. Angeli, V., J. Llodra, J.X. Rong, et al. 2004. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 21: 561-574.
131. Packard, R.R., E.Maganto-Garcia, I. Gotsman, et al. 2008. CD11c(+) dendritic cells maintain antigen processing, presentation capabilities, and CD4(+) T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis. Circ. Res. 103: 965-973.
132. Nickel, T., D. Schmauss, H. Hanssen, et al. 2009. oxLDL uptake by dendritic cells induces upregulation of scavenger-receptors, maturation and differentiation. Atherosclerosis 205: 442-450.
133. Perrin-Cocon, L., F. Coutant, S. Agaugue, et al. 2001. Oxidized low-density lipoprotein promotes mature dendritic cell transition from differentiating monocyte. J. Immunol. 167: 3785-3791.
134. Bluml, S., S. Kirchberger, V.N. Bochkov, et al. 2005. Oxidized phospholipids negatively regulate dendritic cell maturation induced by TLRs and CD40. J. Immunol. 175: 501-508.
135. + monocytes in atherogenesis associated with hypercholesterolemia. Circulation 119: 2708-2717.
136. Gautier, E.L., T. Huby, F. Saint-Charles, et al. 2009. Conventional dendritic cells at the crossroads between immunity and cholesterol homeostasis in atherosclerosis. Circulation 119: 2367-2375.
137. Hermansson, A., D.F. Ketelhuth, D. Strodthoff, et al. 2010. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J. Exp. Med. 207: 1081-1093.
138. Lindquist, R.L., G. Shakhar, D. Dudziak, et al. 2004. Visualizing dendritic cell networks in vivo. Nat. Immunol. 5: 1243-1250.
139. Buono, C., H. Pang, Y. Uchida, et al. 2004. B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 109: 2009-2015.
140. Jeon, H.J., J.H. Choi, I.H. Jung, et al. 2010. CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. Circulation 121: 1124-1133.
141. Nakano, M., Y. Fukumoto, K. Satoh, et al. 2010. OX40 ligand plays an important role in the development of atherosclerosis through vasa vasorum neovascularization. Cardiovasc. Res. 88: 539-546.
142. Foks, A.C., G.H. vanPuijvelde, I. Bot, et al. 2013. Interruption of the OX40-OX40 ligand pathway in LDL receptor-deficient mice causes regression of atherosclerosis. J. Immunol. 191: 4573-4580.
143. Choi, J.H., C. Cheong, D.B. Dandamudi, et al. 2011. Flt3 signaling-dependent dendritic cells protect against atherosclerosis. Immunity 35: 819-831.
144. Lievens, D., K.L. Habets, A.K. Robertson, et al. 2012. Abrogated transforming growth factor beta receptor II (TGFbetaRII) signalling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis. Eur. Heart J. 34: 3717-3727
145. Weber, C., S. Meiler, Y. Doring, et al. 2011. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J. Clin. Invest. 121: 2898-2910.
146. Gotsman, I., N. Grabie, R. Dacosta, et al. 2007. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J. Clin. Invest. 117: 2974-2982.
147. Subramanian, M., E. Thorp, G.K. Hansson & I. Tabas. 2013. Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. J. Clin. Invest. 123: 179-188.
148. Reizis, B., A. Bunin, H.S. Ghosh, et al. 2011. Plasmacytoid dendritic cells: recent progress and open questions. Annu. Rev. Immunol. 29: 163-183.
149. Daissormont, I.T., A. Christ, L. Temmerman, et al. 2011. Plasmacytoid dendritic cells protect against atherosclerosis by tuning T-cell proliferation and activity. Circ. Res. 109: 1387-1395.
150. Niessner, A., K. Sato, E.L. Chaikof, et al. 2006. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation 114: 2482-2489.
151. Doring, Y. & A. Zernecke. 2012. Plasmacytoid dendritic cells in atherosclerosis. Front. Physiol. 3: 230.
152. Salagianni, M., I.E. Galani, A.M. Lundberg, et al. 2012. Toll-like receptor 7 protects from atherosclerosis by constraining "inflammatory" macrophage activation. Circulation 126: 952-962.
153. Doring, Y., H.D. Manthey, M. Drechsler, et al. 2012. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation 125: 1673-1683.
154. Macritchie, N., G. Grassia, S.R. Sabir, et al. 2012. Plasmacytoid dendritic cells play a key role in promoting atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 32: 2569-2579.
155. Ketelhuth, D.F., A. Gistera, D.K. Johansson & G.K. Hansson. 2013. T cell-based therapies for atherosclerosis. Curr. Pharm. Des. 19: 5850-5858.